Overview of Ovarian Cancer
Ovarian cancer ranks among the leading causes of gynecological cancer-related fatalities in women. This disease is particularly deadly, with a high mortality rate attributed to late-stage diagnoses, where cancer has often spread beyond the ovaries into the peritoneal cavity.
Treatment Options for Advanced-Stage Ovarian Cancer
For advanced-stage ovarian cancer, treatment typically involves surgery aimed at reducing tumor size, followed by six cycles of systemic chemotherapy. Alternatively, some patients may receive three cycles of chemotherapy before undergoing interval cytoreductive surgery.
Intraperitoneal Chemotherapy Study
Recent research from the Netherlands explored the effectiveness of standard treatment versus intraperitoneal chemotherapy for ovarian cancer. The study, published in The New England Journal of Medicine in January 2018, investigated whether direct delivery of chemotherapy drugs to the peritoneal surfaces could enhance outcomes.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
One innovative technique discussed in the study is hyperthermic intraperitoneal chemotherapy (HIPEC). This method uses elevated temperatures to improve drug diffusion, making cancer cells more susceptible to treatment. Hyperthermia also facilitates cancer cell destruction and inhibits new blood vessel formation, which cancer cells rely on for growth.
Study Design and Methodology
The study involved 245 patients newly diagnosed with stage III ovarian, fallopian tube, or peritoneal cancer, all with normal blood counts and adequate kidney function. Participants were randomly assigned to either the surgery-plus-HIPEC group or the surgery-only group.
HIPEC Administration
In the surgery-plus-HIPEC group, the abdominal temperature was maintained at 40°C (104°F) during the procedure. Following cytoreductive surgery, the peritoneal cavity was perfused with cisplatin. After perfusion, drains were placed to effectively empty the abdominal cavity. Participants then underwent three additional cycles of paclitaxel and carboplatin chemotherapy.
Outcomes of the Study
Researchers monitored ovarian cancer markers in the blood and conducted computed tomography scans at intervals post-chemotherapy. Participants provided questionnaires regarding their health-related quality of life throughout the treatment process. The study aimed to compare the time until recurrence, progression, or death between the two groups.
Results
Among the 123 patients who underwent surgery without HIPEC, 110 (89%) experienced disease recurrence or death, with a median recurrence-free survival of 10.7 months. In contrast, 99 of the 122 patients (81%) in the surgery-plus-HIPEC group faced recurrence or death, enjoying a median recurrence-free survival of 14.2 months. The median overall survival was 33.9 months for the surgery group and 45.7 months for the HIPEC group.
Conclusion
The findings of this significant study highlight the potential of hyperthermic chemotherapy as an effective treatment option for advanced ovarian cancer. The research indicates that combining HIPEC with surgery can lead to longer recurrence-free survival and improved overall survival compared to surgery alone.
Written by Kimberly Spencer B.Sc. (Hons)
References: van Driel, W., Koole, S., Sikorska, K., Schagen van Leeuwen, J., Schreuder, H., & Hermans, R. et al. (2018). Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. New England Journal Of Medicine, 378(3), 230-240.